Company’s 36-month beta value is 0.57.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ATHE is 8.46M, and currently, short sellers hold a 1.00% ratio of that floaft. The average trading volume of ATHE on February 05, 2025 was 484.96K shares.
ATHE) stock’s latest price update
The stock price of Alterity Therapeutics Ltd ADR (NASDAQ: ATHE) has dropped by -9.62 compared to previous close of 4.99. Despite this, the company has seen a gain of 53.40% in its stock price over the last five trading days. globenewswire.com reported 2025-01-30 that – Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – – ATH434 Demonstrated a Favorable Safety Profile – – Webcast Held Yesterday with Access to the Recording Below – MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy (MSA). The topline data showed that ATH434 produced clinically and statistically significant improvement on the modified UMSARS Part I, a functional rating scale that assesses disability on activities of daily living affected in MSA1.
ATHE’s Market Performance
ATHE’s stock has risen by 53.40% in the past week, with a monthly rise of 28.86% and a quarterly rise of 290.41%. The volatility ratio for the week is 21.70% while the volatility levels for the last 30 days are 15.05% for Alterity Therapeutics Ltd ADR The simple moving average for the past 20 days is 21.79% for ATHE’s stock, with a 140.13% simple moving average for the past 200 days.
Analysts’ Opinion of ATHE
Maxim Group, on the other hand, stated in their research note that they expect to see ATHE reach a price target of $8. The rating they have provided for ATHE stocks is “Buy” according to the report published on December 12th, 2024.
ATHE Trading at 68.48% from the 50-Day Moving Average
After a stumble in the market that brought ATHE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.17% of loss for the given period.
Volatility was left at 15.05%, however, over the last 30 days, the volatility rate increased by 21.70%, as shares surge +36.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +308.14% upper at present.
During the last 5 trading sessions, ATHE rose by +53.40%, which changed the moving average for the period of 200-days by +71.48% in comparison to the 20-day moving average, which settled at $3.70. In addition, Alterity Therapeutics Ltd ADR saw 36.25% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ATHE
Current profitability levels for the company are sitting at:
- -5.88 for the present operating margin
- 0.96 for the gross margin
The net margin for Alterity Therapeutics Ltd ADR stands at -4.76. The total capital return value is set at -1.71. Equity return is now at value -102.86, with -80.90 for asset returns.
Based on Alterity Therapeutics Ltd ADR (ATHE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -79.26.
Currently, EBITDA for the company is -19.57 million with net debt to EBITDA at 0.54. When we switch over and look at the enterprise to sales, we see a ratio of 12.8. The receivables turnover for the company is 0.99for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.54.
Conclusion
In a nutshell, Alterity Therapeutics Ltd ADR (ATHE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
